Investor Presentation for quarter and half year ended September 30, 2026

Date: 4th November, 2026 The Manager, The Manager, Corporate Filings Department, Listing Compliance Department, BSE Limited, National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot no. C/1, G Block, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai- 400 001 Mumbai - 400 051. Security Code: 532815 Symbol: SMSPHARMA Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing here herewith a copy of investor presentation of the Company for the second quarter and half year ended 30th September, 2026. This Investor Presentation may also be accessed on the website of the Company at www.smspharma.com Kindly take the same on record and disseminate on your website. Thanking you Yours Faithfully For SMS Pharmaceuticals Limited Thirumalesh Tumma Company Secretary Investor Presentation Q2FY27 NOVEMBER 2026 Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by SMS Pharmaceuticals Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. www.smspharma.com 2 PERFORMANCE REVIEW www.smspharma.com Executive summary • Revenue up 30% YoY, driven by strong volume growth and improved price realization • Gross margin (Incl. mfg. expenses) increased to 35%, reflecting the tangible benefits of backward integration • EBITDA margin expanded 145 bps YoY to 21%, due to operating leverage • PAT up 57% YoY to ₹40 crore • Completed 6 DMF/CEP filings in FY27 to date; on track to meet the full-year target of 10 DMF/CEP filings in FY27 • FY27 revenue growth and EBITDA margins are now expected to exceed earlier guidance • ₹280 crore capital expenditure program remains on track for completion by FY27 • Peptides R&D facility is now fully operational and pilot scale production is targeted for Q4FY27, with initial CRO revenue from pilot scale production anticipated in Q2FY28 www.smspharma.com 4 Q2FY27 financial highlights REVENUE (₹ CRORE) EBITDA & EBITDA MARGIN PAT & PAT MARGIN* EPS (₹) 316 EBITDA (₹ Cr) Margin (%) PAT (₹ Cr) Margin (%) 4.26 242 238 20% 21% 20% 21% 10% 11% 40 3.58 210 207 17% 68 10% 2.84 2.59 2.23 48 25 23 44 40 41 21 20 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 316 68 40 4.26 ₹ crore ₹ crore ₹ crore ₹ Revenue from operations EBITDA PAT EPS ▲ 30% ▲ 40% ▲ 57% ▲50% ▲ YoY; *PAT and PAT margin exclude share of profit/(loss) from associate. www.smspharma.com 5 H1FY27 financial highlights REVENUE (₹ CRORE) EBITDA & EBITDA MARGIN PAT & PAT MARGIN* EPS (₹) 6.49 EBITDA (₹ Cr) Margin (%) PAT (₹ Cr) Margin (%) 5.13 88 21% 11% H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 H1FY26 H1FY27 523 109 60 6.49 ₹ crore ₹ crore ₹ crore ₹ Revenue from operations EBITDA PAT EPS ▲ 19% ▲ 24% ▲ 36% ▲ 27% ▲ YoY; *PAT and PAT margin exclude share of profit/(loss) from associate. www.smspharma.com 6 Key operating metrics Q2FY27 REVENUE BY GEOGRAPHY (%) REVENUE BY THERAPEUTIC AREA (%) 4% 5% 7% 15% 15% 13% 4% 6% 10% 18% 6% 6% 6% 4% 7% 5% 7% 8% 6% 5% 5% 5% 2% 6% 27% 10% 36% 32% 10% 41% 34% 13% 7% 12% 18% 20% 24% 26% 32% 9% 29% 38% 32% 27% 4% 29% 5% 18% 10% 10% 9% 8% 14% Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 Anti-diabetic Anti Retro Viral (ARV) Europe Asia (Ex. India) North America EOU/SEZ/DE India Anti-inflammatory Anti-migraine Anti-ulcer Anti-erectile dysfunction Anti-epileptic Anti-anginal Others www.smspharma.com 7 Key operating metrics H1FY27 REVENUE BY THERAPEUTIC AREA (%) REVENUE BY GEOGRAPHY (%) 4% 7% 13% 14% 5% 4% 5% 6% 3% 25% H1FY26 H1FY27 H1FY26 H1FY27 Anti-diabetic Anti Retro Viral (ARV) Anti-inflammatory Anti-migraine Anti-ulcer Anti-erectile dysfunction Anti-epileptic Anti-anginal Others Europe Asia (Ex. India) North America EOU/SEZ/DE India www.smspharma.com 8 COMPANY OVERVIEW www.smspharma.com SMS Pharma at a glance 1 Diversified API player with a global presence Established in 2 Globally compliant manufacturing facilities 1989 37 years in API manufacturing 3 Global and domestic leadership in key products and development SMS’s business model is 4 Vertically integrated across product portfolio underpinned by its scale of operations and depth 5 Strong presence in regulated markets of capabilities 6 Strategic focus on R&D www.smspharma.com 10 Key facts #1 55+ 88% Global and Domestic leadership in APIs across 14 diverse therapeutic Revenue from regulated markets key products segments. 3,120 1,600+ 75+ Reactor volume Employees Countries where we have a presence 130+ 200+ 800+ DMFs filed till date Scientists in R&D Customers www.smspharma.com 11 Ready for the next stage of growth… 1989-2011 2011-2017 2017-2022 2022-2025 • Became the world’s largest • Started a greenfield project • Demerger of SMS • Launched Asia’s largest Future manufacturer of Ranitidine in Vizag to build an API lifesciences to unlock dedicated automated API facility in more than 100 operational efficiencies and ibuprofen production block acres of land further increase focus on Focused • Acquired a facility to • Backward integration high-value molecules manufacture high value • Investment in VKT Pharma, projects to improve strategy in place products in Hyderabad an associate company, for • Established leadership margins across product to deliver forward integration position in anti-migraine, portfolio • Successful expansion into regulated markets • Rising market share of high anti-diabetic, anti-ulcer and • Successful audits and revenue growth ARVs etc. value in the regulated ins [Showing first 8,000 characters — download PDF for full document]